Chimeric antigen receptor T (CAR-T) cell therapy is a promising and precise targeted
therapy for cancer that has demonstrated notable potential in clinical applications. However …

In recent years, the field of cancer treatment has witnessed remarkable breakthroughs that
have revolutionized the landscape of care for cancer patients. While traditional pillars such …

Chimeric antigen receptor (CAR) T-cell therapy has achieved substantial clinical outcomes
for tumors, especially for hematological malignancies. However, extending the duration of …

The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic
shift since the dawn of the current century. This has been driven largely by the introduction of …

Advanced Therapy Medicinal Products (ATMPs) based on somatic cells expanded in vitro,
with or without genetic modification, is a rapidly growing area of drug development, even …

Background: Chimeric antigen receptor T cells treatment targeting B cell maturation antigen
(BCMA) is an emerging treatment option for relapsed/refractory multiple myeloma (RRMM) …

Simple Summary The administration of chimeric antigen receptor (CAR)-T cell therapies in
an outpatient setting is expanding; however, there is limited evidence comparing outcomes …

The extracellular matrix (ECM) governs a wide spectrum of cellular fate processes, with a
particular emphasis on anoikis, an integrin‐dependent form of cell death. Currently, anoikis …

To address the dearth of therapeutic options available for relapsed-refractory multiple
myeloma (RRMM), attention has shifted to immunotherapeutic strategies, with most products …

Chimeric antigen receptor (CAR) T-cell therapy is an effective, individualized
immunotherapy, and novel treatment for hematologic malignancies. Six commercial CAR-T …